Differentiating members of the thiazolidinedione class: A focus on safety

Diabetes/Metabolism Research and Reviews

Volumn 18, Issue SUPPL. 2, 2002, Pages

  Lebovitz, Harold E ^a,b  

^a STATE UNIVERSITY OF NEW YORK   (United States)

^b NONE   (United States)

Author keywords

Hepatotoxicity; Pioglitazone; Rosiglitazone; Safety; Thiazolidinediones; Type 2 diabetes

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; ATORVASTATIN; CREATINE KINASE; CYCLOSPORIN; CYTOCHROME; CYTOCHROME C2; CYTOCHROME P450 2C8; CYTOCHROME P450 3A4; DIGOXIN; DIURETIC AGENT; ETHINYLESTRADIOL; GLIBENCLAMIDE; HEMOGLOBIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; ISOPROTEIN; KETOCONAZOLE; LEVONORGESTREL; LIPID; METFORMIN; NIFEDIPINE; ORAL CONTRACEPTIVE AGENT; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PIOGLITAZONE; RANITIDINE; ROSIGLITAZONE; TERFENADINE; TROGLITAZONE; UNCLASSIFIED DRUG; UNINDEXED DRUG; WARFARIN;

ARTICLE; CLINICAL PRACTICE; CLINICAL STUDY; CONTROLLED STUDY; DRUG BINDING; DRUG CLASSIFICATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG STRUCTURE; EDEMA; HEMATOCRIT; HEMOGLOBIN DETERMINATION; HUMAN; LIPID BLOOD LEVEL; LIVER TOXICITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RECEPTOR AFFINITY; RECEPTOR UPREGULATION; STRUCTURE ACTIVITY RELATION; WEIGHT GAIN;

CHROMANS; DIABETES MELLITUS, TYPE 2; DRUG INTERACTIONS; HUMANS; HYPOGLYCEMIC AGENTS; LIVER; SAFETY; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0036250329     PISSN: 15207552     EISSN: None     Source Type: Journal    
DOI: 10.1002/dmrr.252     Document Type: Article

References (40)

1. Rosiglitazone
2. Rosiglitazone is superior to glyburide in reducing fasting plasma glucose in type 2 diabetic patients
3. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: A randomized, placebo-controlled study
4. Rosiglitazone is safe and well tolerated as monotherapy or combination therapy in patients with Type 2 diabetes mellitus
5. Rosiglitazone (RSG) improves fasting and post-prandial plasma glucose in Type 2 diabetes
6. Pioglitazone is effective in the treatment of patients with type 2 diabetes
7. Troglitazone monotherapy improves glycaemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
8. Troglitazone, an insulin action enhancer, improves glycaemic control and insulin sensitivity in elderly type 2 diabetic patients
9. Pioglitazone (AD-4833) ameliorates insulin resistance in patients with NIDDM
10. Effects of troglitazone: A new hypoglycemic agent in patients with NIDDM poorly controlled by diet therapy
11. Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers
12. Rosiglitazone has no clinically significant effect on nifedipine pharmacokinetics
13. Hepatic dysfunction associated with troglitazone
14. Toxicity of troglitazone in cultured rat hepatocytes
15. Activators of peroxisome proliferator-activated receptor gamma have depot-specific effects on human preadipocyte differentiation
16. Disposition and metabolism of the new oral antidiabetic drug troglitazone in rats, mice and dogs
17. Fatal hepatotoxicity associated with troglitazone
18. Troglitazone-induced hepatic failure leading to liver transplantation. A case report
19. Two cases of severe clinical and histologic hepatotoxicity associated with troglitazone
20. Rosiglitazone therapy is not associated with hepatotoxicity
21. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes
22. Characterisation of the P450 enzymes involved in the in vitro metabolism of rosiglitazone
23. Clinical pharmacokinetics of troglitazone
24. Rosiglitazone does not markedly alter CYP3A4-mediated drug metabolism
25. Rosiglitazone does not alter the pharmacokinetics of metformin
26. Rosiglitazone does not affect the steady-state pharmacokinetics of digoxin
27. Rosiglitazone pharmacokinetics are not affected by coadministration of ranitidine
28. Pioglitazone has low potential for drug interactions
29. Rosiglitazone: No effect on erythropoiesis red cell destruction
30. Troglitazone has no effect on red cell mass or other erythropoietic parameters
31. Effect of troglitazone on body fat distribution in type 2 diabetic patients
32. Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes
33. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus
34. The small, dense LDL phenotype and the risk of coronary heart disease: Epidemiology, patho-physiology and therapeutic aspects
35. Troglitazone decreases the proportion of small, dense LDL and increases the resistance of LDL to oxidation in obese subjects
36. The insulin sensitizer, BRL 49653, reduces systemic fatty acid supply and utilization and tissue lipid availability in the rat
37. Once-, twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes